PubMed:28826027
Annnotations
PubTator4TogoVar
Id | Subject | Object | Predicate | Lexical cue | proteinmutation |
---|---|---|---|---|---|
28826027_0 | 55-61 | ProteinMutation | denotes | G2019S | rs34637584 |
28826027_1 | 166-174 | ProteinMutation | denotes | p.G2019S | rs34637584 |
28826027_2 | 404-410 | ProteinMutation | denotes | G2019S | rs34637584 |
28826027_3 | 655-661 | ProteinMutation | denotes | G2019S | rs34637584 |
28826027_4 | 893-899 | ProteinMutation | denotes | G2019S | rs34637584 |
28826027_5 | 962-968 | ProteinMutation | denotes | G2019S | rs34637584 |
28826027_6 | 1306-1312 | ProteinMutation | denotes | G2019S | rs34637584 |
28826027_7 | 1454-1460 | ProteinMutation | denotes | G2019S | rs34637584 |
c_corpus
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-6 | SO:0001459 | denotes | CRISPR |
T14 | 7-10 | UBERON:0002920 | denotes | Cas |
T4 | 7-10 | GO:0005650 | denotes | Cas |
T18 | 7-10 | D001072 | denotes | Cas |
T20 | 7-11 | Q03LF7 | denotes | Cas9 |
T21 | 7-11 | Q03JI6 | denotes | Cas9 |
T22 | 7-11 | CVCL_8537 | denotes | Cas9 |
T23 | 49-54 | PR:Q5S006 | denotes | LRRK2 |
T24 | 49-54 | PR:000003033 | denotes | LRRK2 |
T25 | 49-54 | PR:Q5S007 | denotes | LRRK2 |
T26 | 116-125 | D051843 | denotes | Synuclein |
T27 | 116-125 | P37379 | denotes | Synuclein |
T28 | 175-183 | SO:0000109 | denotes | mutation |
T30 | 191-198 | 6308 | denotes | leucine |
T31 | 191-198 | SO:0001437 | denotes | leucine |
T29 | 191-198 | CHEBI:15603 | denotes | leucine |
T32 | 191-198 | D007930 | denotes | leucine |
T33 | 191-198 | CHEBI:25017 | denotes | leucine |
T34 | 191-198 | D007930 | denotes | leucine |
T35 | 204-210 | SO:0001068 | denotes | repeat |
T36 | 221-226 | PR:Q5S006 | denotes | LRRK2 |
T37 | 221-226 | PR:000003033 | denotes | LRRK2 |
T38 | 221-226 | PR:Q5S007 | denotes | LRRK2 |
T43 | 309-328 | D010300 | denotes | Parkinson's disease |
T44 | 309-328 | D010300 | denotes | Parkinson's disease |
T47 | 339-342 | SO:0001843 | denotes | Cre |
T48 | 398-403 | PR:Q5S006 | denotes | LRRK2 |
T49 | 398-403 | PR:000003033 | denotes | LRRK2 |
T50 | 398-403 | PR:Q5S007 | denotes | LRRK2 |
T51 | 411-419 | SO:0000109 | denotes | mutation |
T52 | 439-444 | D006801 | denotes | human |
T53 | 548-557 | SO:0000346 | denotes | LoxP site |
T54 | 572-576 | SO:0000704 | denotes | gene |
T55 | 572-587 | GO:0010467 | denotes | gene expression |
T56 | 649-654 | PR:Q5S006 | denotes | LRRK2 |
T57 | 649-654 | PR:000003033 | denotes | LRRK2 |
T58 | 649-654 | PR:Q5S007 | denotes | LRRK2 |
T59 | 686-692 | SO:0000116 | denotes | edited |
T60 | 702-708 | SO:0001459 | denotes | CRISPR |
T73 | 709-712 | UBERON:0002920 | denotes | Cas |
T63 | 709-712 | GO:0005650 | denotes | Cas |
T77 | 709-712 | D001072 | denotes | Cas |
T79 | 709-713 | Q03LF7 | denotes | Cas9 |
T80 | 709-713 | Q03JI6 | denotes | Cas9 |
T81 | 709-713 | CVCL_8537 | denotes | Cas9 |
T83 | 776-784 | 10962 | denotes | Tyrosine |
T87 | 776-784 | SO:0001446 | denotes | Tyrosine |
T90 | 776-796 | A0A060X6Z0 | denotes | Tyrosine Hydroxylase |
T89 | 776-796 | D014446 | denotes | Tyrosine Hydroxylase |
T91 | 832-839 | GO:0043005 | denotes | neurite |
T96 | 887-892 | PR:Q5S006 | denotes | LRRK2 |
T97 | 887-892 | PR:000003033 | denotes | LRRK2 |
T98 | 887-892 | PR:Q5S007 | denotes | LRRK2 |
T99 | 956-961 | PR:Q5S006 | denotes | LRRK2 |
T100 | 956-961 | PR:000003033 | denotes | LRRK2 |
T101 | 956-961 | PR:Q5S007 | denotes | LRRK2 |
T102 | 1074-1081 | GO:0043005 | denotes | neurite |
T109 | 1118-1124 | 9671 | denotes | Serine |
T111 | 1118-1124 | SO:0001444 | denotes | Serine |
T107 | 1118-1124 | D012694 | denotes | Serine |
T108 | 1118-1124 | CHEBI:17822 | denotes | Serine |
T110 | 1118-1124 | D012694 | denotes | Serine |
T112 | 1118-1124 | CHEBI:17115 | denotes | Serine |
T114 | 1152-1167 | P37840 | denotes | alpha-Synuclein |
T115 | 1152-1167 | Q91448 | denotes | alpha-Synuclein |
T117 | 1152-1167 | P61140 | denotes | alpha-Synuclein |
T118 | 1152-1167 | Q3T0G8 | denotes | alpha-Synuclein |
T119 | 1152-1167 | P61139 | denotes | alpha-Synuclein |
T120 | 1152-1167 | P61146 | denotes | alpha-Synuclein |
T121 | 1152-1167 | P61141 | denotes | alpha-Synuclein |
T122 | 1152-1167 | P61144 | denotes | alpha-Synuclein |
T123 | 1152-1167 | PR:000015322 | denotes | alpha-Synuclein |
T124 | 1152-1167 | P61147 | denotes | alpha-Synuclein |
T125 | 1152-1167 | O55042 | denotes | alpha-Synuclein |
T126 | 1152-1167 | Q3I5G7 | denotes | alpha-Synuclein |
T127 | 1152-1167 | P61142 | denotes | alpha-Synuclein |
T128 | 1152-1167 | P37377 | denotes | alpha-Synuclein |
T129 | 1152-1167 | P61138 | denotes | alpha-Synuclein |
T130 | 1152-1167 | P61143 | denotes | alpha-Synuclein |
T131 | 1152-1167 | P61145 | denotes | alpha-Synuclein |
T116 | 1152-1167 | D051844 | denotes | alpha-Synuclein |
T134 | 1241-1250 | GO:0009058 | denotes | formation |
T135 | 1300-1305 | PR:Q5S006 | denotes | LRRK2 |
T136 | 1300-1305 | PR:000003033 | denotes | LRRK2 |
T137 | 1300-1305 | PR:Q5S007 | denotes | LRRK2 |
T138 | 1448-1453 | PR:Q5S006 | denotes | LRRK2 |
T139 | 1448-1453 | PR:000003033 | denotes | LRRK2 |
T140 | 1448-1453 | PR:Q5S007 | denotes | LRRK2 |
T141 | 1481-1493 | GO:0009405 | denotes | pathogenesis |
PubMed_ArguminSci
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 162-334 | DRI_Background | denotes | The p.G2019S mutation of the leucine-rich repeat kinase 2 (LRRK2) has been identified as the most prevalent genetic cause of familial and sporadic Parkinson's disease (PD). |
T2 | 335-524 | DRI_Background | denotes | The Cre-LoxP recombination system has been used to correct the LRRK2-G2019S mutation in patient derived human induced pluripotent stem cells (hiPSCs) in order to generate isogenic controls. |
T3 | 525-588 | DRI_Background | denotes | However, the remaining LoxP site can influence gene expression. |
T4 | 589-633 | DRI_Approach | denotes | In this study, we report the generation of a |
T5 | 671-740 | DRI_Approach | denotes | hiPS cell line edited with the CRISPR/Cas9 and piggyBac technologies. |
T6 | 741-926 | DRI_Outcome | denotes | We observed that the percentage of Tyrosine Hydroxylase (TH) positive neurons with a total neurite length of >2000μm was significantly reduced in LRRK2-G2019S dopaminergic (DA) neurons. |
T7 | 927-999 | DRI_Outcome | denotes | The average branch number in LRRK2-G2019S DA neurons was also decreased. |
T8 | 1000-1268 | DRI_Outcome | denotes | In addition, we have shown that in vitro TH positive neurons with a total neurite length of >2000μm were positive for Serine 129 phosphorylated (S129P) alpha-Synuclein (αS) and we hypothesize that S129P-αS plays a role in the maintenance or formation of long neurites. |
T9 | 1269-1284 | DRI_Approach | denotes | In summary, our |
T10 | 1322-1500 | DRI_Approach | denotes | cell lines allow standardized, genetic background independent, in vitro PD modeling and provide new insights into the role of LRRK2-G2019S and S129P-αS in the pathogenesis of PD. |